Wisconsin is currently home to 1355 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Systematic Efficacy Replication Study of Conjoint Behavioral Consultation in Elementary Schools
NCT05466214
Recruiting
The purpose of this project is to conduct an impact evaluation of the Conjoint Behavioral Consulting (CBC) intervention under real-world conditions as an IES Efficacy Replication trial. CBC is a family-school partnership intervention proven efficacious for children with serious emotional and behavior problems. The investigation will conduct a systematic efficacy replication of CBC to identify important process and context variables in need of attention prior to a CBC effectiveness study. School-... Read More
Gender:
All
Ages:
Between 4 years and 10 years
Trial Updated:
02/07/2023
Locations: Madison Metropolitan School District, Madison, Wisconsin
Conditions: Emotional Disturbances
Register for Updates
GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS
NCT05266001
Recruiting
The GRACE-2 study is a prospective, multi-center, double-blind, randomized controlled trial of the drug GM-CSF vs placebo in children with sepsis-induced multiple organ dysfunction syndrome (MODS) who have immunoparalysis with mild to moderate inflammation.
Gender:
All
Ages:
Between 1 day and 17 years
Trial Updated:
02/07/2023
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome
Register for Updates
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
NCT05267821
Recruiting
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
Gender:
All
Ages:
Between 1 day and 17 years
Trial Updated:
02/07/2023
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Register for Updates
EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study
NCT05610787
Recruiting
The purpose of this study is to evaluate the device performance and monitor the safety and effectiveness of the Berlin Heart EXCOR Active Driving System while being used with the approved EXCOR Pediatric Ventricular Assist Device. EXCOR Active Driving System is intended for use with the approved EXCOR Pediatric VAD. The EXCOR Pediatric VAD is intended to provide mechanical circulatory support as a bridge to cardiac transplantation for pediatric patients. Pediatric candidates with severe isolat... Read More
Gender:
All
Ages:
21 years and below
Trial Updated:
02/06/2023
Locations: Children's Hospital Wisconsin, Milwaukee, Wisconsin
Conditions: Heart Failure, Transplant; Failure, Heart, Congenital Heart Disease
Register for Updates
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
NCT05210283
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Marshfield Medical Center Weston, Weston, Wisconsin
Conditions: Colorectal Cancer
Register for Updates
Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)
NCT04502316
Recruiting
The purpose of this registry is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients with heart failure with reduced ejection fraction (HFrEF) that were recently implanted with the Barostim System.
Gender:
All
Ages:
All
Trial Updated:
01/21/2023
Locations: Marshfield Medical Center - Weston, Weston, Wisconsin
Conditions: Heart Failure
Register for Updates
Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis
NCT04316442
Recruiting
The STI-6129-001 study is a three-stage, multicenter, open-label, dose-finding, phase 1b/2a trial. It is designed primarily to identify the recommended phase 2 dose (RP2D) of STI-6129 by assessing the safety, preliminary efficacy and pharmacokinetics of this anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC) for the treatment of relapsed or refractory systemic AL amyloidosis. The patients that will be treated with STI-6129 in this trial are relapsed or refractory systemic AL amyloidosis pati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2023
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Light Chain (AL) Amyloidosis
Register for Updates
Preeclampsia Postpartum Antihypertensive Treatment
NCT04298034
Recruiting
The goal of this study is to compare whether antihypertensive treatment in the postpartum period decreases postpartum hypertension and its associated maternal morbidity, including risk of readmission and healthcare utilization in comparison with no treatment. Women with preeclampsia diagnosed during the antepartum, intrapartum or postpartum period will be randomized to either initiate antihypertensive treatment or standard of care. We hypothesize that postpartum antihypertensive treatment of pat... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/01/2023
Locations: Medical College of Wisconsin-Froedtert Hospital, Milwaukee, Wisconsin
Conditions: Preeclampsia, Hypertension in Pregnancy
Register for Updates
StimRouter Registry Clinical Protocol
NCT03913689
Recruiting
This Registry study will prospectively evaluate the long-term effectiveness, safety, and tolerability of the StimRouter Neuromodulation System, along with evaluating the technical performance of StimRouter, surgical outcomes, health-related quality of life, concomitant medical use, and subject's impression of improvement.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/07/2022
Locations: Advocate Aurora Health, Oshkosh, Wisconsin
Conditions: Chronic Pain, Peripheral Neuropathy, Nervous System Diseases, Peripheral Nervous System Diseases, Peripheral Nervous System Problem, Peripheral Nerve Injuries, Peripheral Nervous
Register for Updates
Attentional Bias Modification Training for E-cigarette Users
NCT05112562
Recruiting
Aims are to (1) evaluate attentional bias to e-cigarette cues between the intervention and control groups at post-intervention as compared to the pre-intervention; and (2) test the feasibility and efficacy of the intervention at post-intervention. To accomplish these aims, a theory-driven parallel, controlled 2-arm randomized clinical trial will be conducted with young adult e-cigarette users (approximately N = 50). Outcomes are attentional bias to e-cigarette cues and abstinence outcomes includ... Read More
Gender:
All
Ages:
Between 18 years and 29 years
Trial Updated:
11/01/2022
Locations: University of Wisconsin-Milwaukee, Milwaukee, Wisconsin
Conditions: E-cigarette Use, Tobacco Use Cessation
Register for Updates
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers
NCT05255107
Recruiting
This study is being conducted to evaluate the safety and effectiveness of using the PXL Platinum 330 System with riboflavin solution for performing corneal collagen crosslinking (CXL) for the treatment of previously untreated corneal ulcers. The PXL Platinum 330 System is a combination product consisting of an ultraviolet A (UV-A) 365 nm wavelength light source (PXL Platinum 330 Illumination System) and riboflavin (Riboflavin 0.23% PESCHKE-L Solution) administered in conjunction with the UV-A li... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/26/2022
Locations: Milwaukee Eye Surgeons, Milwaukee, Wisconsin
Conditions: Keratitis, Corneal Ulcer
Register for Updates
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers
NCT05255016
Recruiting
This study is being conducted to evaluate the safety and effectiveness of using the PXL Platinum 330 System with riboflavin solution for performing corneal collagen crosslinking (CXL) for the treatment of refractory corneal ulcers. The PXL Platinum 330 System is a combination product consisting of an ultraviolet-A (UV-A) 365 nm wavelength light source (PXL Platinum 330 Illumination System) and riboflavin (Peschke Riboflavin 0.25% Transepithelial Solution) administered in conjunction with the UV-... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/26/2022
Locations: Milwaukee Eye Surgeons, Milwaukee, Wisconsin
Conditions: Keratitis, Corneal Ulcer
Register for Updates